Pigmentary changes in a patient treated with imatinib Journal Article


Authors: Balagula, Y.; Pulitzer, M. P.; Maki, R. G.; Myskowski, P. L.
Article Title: Pigmentary changes in a patient treated with imatinib
Abstract: Imatinib mesylate (STI 571; Gleevec; Novartis Pharmaceuticals, Basel, Switzerland) is an orally available tyrosine kinase inhibitor that targets a constitutively activated BCR-ABL tyrosine kinase with additional inhibitory effects on platelet derived growth factor (PDGF) receptors alpha and beta, and KIT. It has revolutionized the treatment of adult and pediatric patients with Philadelphia chromosome positive chronic myelogenous leukemia (CML) and is also FDA-approved for KIT-positive advanced gastrointestinal tumor (GIST) and dermatofibrosarcoma protuberans. A wide spectrum of dermatologic toxicities has been associated with this agent, among which a maculopapular rash is the most common event. In addition, a variety of pigmentary abnormalities of the skin and mucosal surfaces have been reported. Hypopigmentation is a well-recognized adverse effect. In contrast, paradoxical hyperpigmentation has only rarely been documented. In this case report we describe imatinib-induced cutaneous hyperpigmentation and graying of hair occurring in the same patient with dermatofibrosarcoma protuberans treated with imatinib. Copyright © 2011 Journal of Drugs in Dermatology.
Keywords: adult; human tissue; treatment outcome; prednisone; case report; drug dose reduction; drug safety; drug withdrawal; side effect; antineoplastic agents; skin manifestation; follow-up studies; imatinib; melanin; skin biopsy; skin pigmentation; cell infiltration; epidermis; mucosa inflammation; pyrimidines; keratinocyte; hair color; maculopapular rash; peripheral edema; erythema; hyperpigmentation; histiocyte; physical examination; piperazines; hydrocortisone; periorbital edema; lymphocyte; urticaria; dermatofibrosarcoma; stratum corneum; triamcinolone; dermatofibrosarcoma protuberans; fluocinonide; skin burning sensation; body surface; skin pruritus; betamethasone dipropionate; melanophage; thrush
Journal Title: Journal of Drugs in Dermatology
Volume: 10
Issue: 9
ISSN: 1545-9616
Publisher: Journal of Drugs in Dermatology, Inc.  
Date Published: 2011-09-01
Start Page: 1062
End Page: 1066
Language: English
PROVIDER: scopus
PUBMED: 22052279
DOI/URL:
Notes: --- - "Export Date: 2 November 2011" - "Source: Scopus"
Citation Impact
MSK Authors
  1. Melissa P Pulitzer
    203 Pulitzer
  2. Robert Maki
    240 Maki
  3. Patricia Myskowski
    216 Myskowski